Mayne Pharma has denied US drug maker Cosette’s claims it breached its continuous disclosure obligations in relation to US FDA concerns about marketing for its Nextstellis contraceptive, as the drug makers spar over their $672 million merger.
Genomic sequencing company Oxford Nanopore Technologies has sued MGI Australia alleging infringement of four patents covering nanopore technology.
A class action against aged care provider Bupa faced tough questions by a judge on Monday, who grilled counsel over the case’s theory of loss. And the answers — rather than reassuring her — raised the spectre of a summary judgment fight.
A court has heard US drug maker Cosette may amend its case to accuse Adelaide’s Mayne Pharma of continuous disclosure breaches in their battle over the termination of their $672 million merger.
Mayne Pharma has said it may seek to shut out US drug maker Cosette’s expert evidence in proceedings over the purported termination of their $672 million merger.
A discrimination class action has been filed on behalf of single women and same-sex couples designated “socially infertile” and denied Medicare rebates for IVF.
Flu vaccine maker Seqirus has successfully opposed Moderna’s proposed patent for a mRNA vaccine, but an IP Australia delegate said the problems with the patent can be overcome by amendments.
US biotech company Regeneron Pharmaceuticals has sued Sandoz, claiming it is threatening to infringe the patent for its Eylea biologic, used to treat macular degeneration and diabetic macular oedema.
Private health insurer Bupa has admitted to misleading thousands of customers about their private health insurance benefits and has agreed to cop a $35 million penalty in a case by the consumer watchdog.
The Therapeutic Goods Administration has dragged Mamamia and News Corp-owned Body + Soul magazine to Federal Court over alleged unlawful medicinal cannabis advertising.